{
    "laboratory_examinations": [
        {
            "procedure_name": "Carcinoembryonic antigen",
            "date": "Not specified",
            "findings": "6.5 ng per milliliter (reference range, <3.4)",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Human chorionic gonadotropin",
            "date": "Not specified",
            "findings": "1.2 IU per liter (reference range, <0.7)",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Complete blood count",
            "date": "Not specified",
            "findings": "Normal",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Serum electrolytes, calcium, phosphorus, magnesium, glucose, total protein, albumin, globulin, alkaline phosphatase, lactate dehydrogenase, and alpha-fetoprotein",
            "date": "Not specified",
            "findings": "Normal",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Tests of coagulation and kidney and liver function",
            "date": "Not specified",
            "findings": "Normal",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Fluorescence in situ hybridization (FISH)",
            "date": "Not specified",
            "findings": "Positive for ALK gene rearrangement",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "CT scans before treatment",
            "date": "Before treatment with crizotinib",
            "findings": "Mixed response with improvement in lymphadenopathy but worsening bone disease.",
            "changes_over_time": "After treatment with crizotinib, decrease in the size of paraesophageal lymph-node mass and lung nodules."
        },
        {
            "procedure_name": "Bone scans before and after treatment",
            "date": "Before and after treatment with crizotinib",
            "findings": "Radio-tracer uptake in the metastases in T1 and L4 vertebrae before treatment; decreased uptake after therapy.",
            "changes_over_time": "Improvement in T1 and L4 metastases after treatment."
        }
    ]
}